Bach Pharma, Inc. is dedicated to the discovery, development and commercialization of new therapeutics for the treatment of life threatening oxidative stress-related Diseases And Other Serious Illnesses.

Bach’s lead candidate GVT® is a novel cytoprotective agent. GVT® has powerful anti-oxidant and anti-inflammatory properties and scavenges free radicals. Research has shown that GVT® is a redox buffering molecule, a heavy metal chelator, as well as a regulator of proteostasis and Nrf2. GVT® has the ability to cross the blood-brain barrier and enter cells of the central nervous system, as well as to enter the immune system, thereby delivering therapeutic results to the gut, thymus, spleen and blood. It is also able to cross the retinal-brain barrier.Bach, in collaboration with The University of Texas’s M.D Anderson Cancer Center and Harvard Medical School have assisted and supported ongoing studies and trials with the Company’s products. Additional studies have been or are currently underway at Northwestern University, Texas A&M University, University of Massachusetts Medical School, Baylor University, Colorado State University, University of North Carolina, Duke University, University of South Florida, as well as other universities around the world. The products have been under advanced study by the Department of Defense and The Veterans Administration.



Upcoming Events

Annual Shareholder Meeting            North Andover, MA                            March 18, 2016

800 Turnpike St, Suite 300                               North Andover, MA 01845

Board of Directors Meeting:             North Andover, MA                           March 19, 2016

800 Turnpike St, Suite 300                               North Andover, MA 01845

Press Releases

January 30, 2016

          Possible Hope for Veterans Suffering               from Gulf War Illness

February 10, 2013

Bach Pharma Appoints William S. Lynn as Lifetime Director Emeritus

February 1, 2013

Bach Pharma Appoints Mr. Dan Cato as President

June 30, 2011

Positive Progress for Bach Pharma

April 20, 2011

Foundation for the NIH Launches First U.S-Russia Scientific Forum

January 4, 2010

Bach Pharma announces Preventative Drug Development Program


June 2014